英文药名：Flivas OD Tablets（Naftopidil）

中文药名：萘哌地尔口服崩解片

生产厂家：旭化成制药

フリバスOD錠25mg／フリバスOD錠50mg／フリバスOD錠75mg

治疗类别名称
尿痛引起的良性前列腺增生症改善剂
商標名
Flivas OD Tablets
一般名
ナフトピジル（Naftopidil）
化学名
(2RS)-1-[4-(2-Methoxyphenyl)piperazin-1-yl]-3-(naphthalen-1-yloxy)propan-2-ol
構造式

 
分子式
C24H28N2O3
分子量
392.49
融点
126～129℃
性状
本品是一种白色结晶粉末。
它是在乙酸酐，N，N-二甲基甲非常可溶或易溶于乙酸（100），在甲醇或乙醇（99.5）微溶，并且几乎不溶于水。
该产品将是轻渐浅棕色。
N的产物，N-二甲基甲酰胺溶液（1→10）示出了没有旋光性。
操作注意事项
要保存，避免光线。这种药物可以通过光变色。这些变色，你不要使用。
适应症
改善尿痛引起的良性前列腺增生
用法与用量
成年人，包括施用多于一次25MG1天如萘哌地尔，如果效果是在一到两周的间隔不足，逐渐升高到50-75毫克，饭后口服给药每天一次之后。
此外，虽然根据症状，每天和高达75毫克的最高剂量调整。
包装规格
OD片
25毫克：PTP100片（10片×10），PTP140片（14片×10），PTP500片（10片×50）

50毫克：PTP100片（10片×10），PTP140片（14片×10），PTP500片（10片×50）

75毫克：PTP100片（10片×10），PTP140片（14片×10），PTP500片（10片×50）

制造厂商
旭化成制药株式会社
完整资料附件：http://www.info.pmda.go.jp/go/pack/2590009F4020_1_13/

About the release of urination disorder ameliorating agent "Flibus OD tablet 75 mg"
Asahi Kasei Pharma Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President: Akira Oe) announced today that it will introduce a drug for the treatment of dysuria associated with benign prostatic hyperplasia (BPH) : Naftopidil) *275mg orally disintegrating tablet * 3We will inform you that sales of "Flibus OD tablets 75 mg" will begin on July 25.
Dysuria associated with benign prostatic hypertrophy (BPH) is a disease that male elderly develops, and the number of patients is rapidly increasing in recent years as the aging society advances. Since launching "Flibas tablets 25mg.50mg" targeting the same disease in February 1999, we launched "Flibus 75 mg" in July 2005 and "Flibus OD tablets" in July of last year in the orally disintegrating tablet 50 mg "has been released, and it is widely used as a therapeutic agent for dysuria. By adding "Flibus OD tablets 75 mg" to be released this time, it will be possible to further enhance the convenience when taking patients.
In the case of
We will continue to develop preparations that can respond to various patient's styles of medication and will continue to contribute to the improvement of the quality of life (LOL) of elderly people in an aging society that is accelerating more and more.
* 1Dysuria associated with benign prostatic hypertrophy (BPH)
Prostate hypertrophy (BPH) is a disorder in which the prostate, which is an organ unique to men surrounding the urethra under the bladder, enlarges. Unpleasant symptoms such as urination and nighttime frequent urination occurring when BPH develops and the urethra is pressed are called BPH-associated dysuria.
※ 2 "Flibus"
An α1 receptor blocker that inhibits contraction of prostate by blocking α1 receptor of prostate/urethral smooth muscle involved in the onset of BPH. It has the efficacy of spreading the urethra and improving unpleasant symptoms, and in particular, it is characterized by effective for nocturia.
"Flibus" is a registered trademark.
* 3 Orally disintegrating tablet
A tablet that can be easily taken by elderly people who have deteriorated swallowing function by rapidly dissolving with saliva or a small amount of water in the oral cavity or in patients who are restricted from ingesting moisture during treatment of artificial dialysis.